[HTML][HTML] The selective androgen receptor modulator GTx-024 (enobosarm) improves lean body mass and physical function in healthy elderly men and …

JT Dalton, KG Barnette, CE Bohl, ML Hancock… - Journal of cachexia …, 2011 - Springer
JT Dalton, KG Barnette, CE Bohl, ML Hancock, D Rodriguez, ST Dodson, RA Morton…
Journal of cachexia, sarcopenia and muscle, 2011Springer
Background Cachexia, also known as muscle wasting, is a complex metabolic condition
characterized by loss of skeletal muscle and a decline in physical function. Muscle wasting
is associated with cancer, sarcopenia, chronic obstructive pulmonary disease, end-stage
renal disease, and other chronic conditions and results in significant morbidity and mortality.
GTx-024 (enobosarm) is a nonsteroidal selective androgen receptor modulator (SARM) that
has tissue-selective anabolic effects in muscle and bone, while sparing other androgenic …
Background
Cachexia, also known as muscle wasting, is a complex metabolic condition characterized by loss of skeletal muscle and a decline in physical function. Muscle wasting is associated with cancer, sarcopenia, chronic obstructive pulmonary disease, end-stage renal disease, and other chronic conditions and results in significant morbidity and mortality. GTx-024 (enobosarm) is a nonsteroidal selective androgen receptor modulator (SARM) that has tissue-selective anabolic effects in muscle and bone, while sparing other androgenic tissue related to hair growth in women and prostate effects in men. GTx-024 has demonstrated promising pharmacologic effects in preclinical studies and favorable safety and pharmacokinetic profiles in phase I investigation.
Methods
A 12-week double-blind, placebo-controlled phase II clinical trial was conducted to evaluate GTx-024 in 120 healthy elderly men (>60 years of age) and postmenopausal women. The primary endpoint was total lean body mass assessed by dual energy X-ray absorptiometry, and secondary endpoints included physical function, body weight, insulin resistance, and safety.
Results
GTx-024 treatment resulted in dose-dependent increases in total lean body mass that were statistically significant (P < 0.001, 3 mg vs. placebo) and clinically meaningful. There were also significant improvements in physical function (P = 0.013, 3 mg vs. placebo) and insulin resistance (P = 0.013, 3 mg vs. placebo). The incidence of adverse events was similar between treatment groups.
Conclusion
GTx-024 showed a dose-dependent improvement in total lean body mass and physical function and was well tolerated. GTx-024 may be useful in the prevention and/or treatment of muscle wasting associated with cancer and other chronic diseases.
Springer